A Phase 1 interventional study of Dexmethylphenidate in Healthy Volunteers in Fed and Fasted State, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-20.
Sponsored by Cingulate Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Fasting with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Fasting · United States.
Among the 95 studies in Fasting with a site in United States, this one is the 59th largest by enrollment of the 85 interventional ones that give a count, is one of 6 that started in 2022, is one of 19 in phase 1, and was the 59th registered.
392 studies on the registry are indexed under Fasting; 63 are open to participants now.
Browse Fasting studies →19 of the 95 studies in Fasting with a site in United States are open now. Recruiting first, the newest first:
University of California, San Diego · Sites in United States
Ages 18–75
University of Illinois at Chicago · Sites in United States
Ages 25–99 · Women only
Ayal A. Aizer, MD · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 5 · Phase 3 1 · Phase 4 1
First in 1999; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 45 across 311 interventional studies indexed under Fasting.
Median enrollment 39 across the 85 interventional studies, 42 across the 10 observational. Of the 68 that completed or were terminated, 18 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 95 have an industry lead sponsor. The 10 most frequent:
Cingulate Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Cingulate Therapeutics has 2 studies filed under Fasting — fewer than ten, so there is no comparison to draw.
8 of the studies in Fasting with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387445University of Illinois at ChicagoFeasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer. | 2026-12-31 |
| NCT04893226Julie PendergastCircadian Rhythms in Postmenopausal Women | 2027-01-31 |
| NCT06884059University of California, San DiegoTime Restricted Eating in Patients With Microalbuminuria | 2027-02 |
| NCT05545306National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure | 2027-02-02 |
| NCT03523377Memorial Sloan Kettering Cancer CenterOvernight Fasting After Completion of Therapy: The OnFACT Study | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Fasting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the effect of food on the rate and extent of absorption and the overall bioavailability of a single dose of CTx-1301 25 mg trimodal tablets in healthy adult volunteers.
An open-label, randomized, single-dose, two-sequence, two-period, in-clinic crossover study with two treatments (fed vs fasted) in approximately 26 healthy adult subjects aged 18 to 50 years.
Fed arm: Following an overnight fast of 10.5 hours, subjects should begin and finish consuming the test meal within 30 minutes, prior to administration of CTx-1301 (25 mg). CTx-1301 (25 mg) should be administered with approximately 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for at least one hour before and at least one hour after drug administration. Subjects should receive standardized meals as defined in the study schedule for the fed treatment arm.
Fasted arm: Following an overnight fast of 10.5 hours, subjects should be administered CTx-1301 (25 mg) with approximately 240 mL (8 fluid ounces) of water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired except for at least one hour before and at least one hour after drug administration. Subjects should receive standardized meals as defined in the study schedule for the fasted treatment arm.
A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal is used as the test meal for food-effect bioanalytical (BA) and fed bioequivalency (BE) studies. This test meal allows approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively. The test meal, eaten within 30 minutes prior to administration of CTx-1301, is two eggs fried in butter, two strips of bacon, two slices of toast with butter, four ounces of hash brown potatoes and eight ounces of whole milk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
Weight and
Compliance
Consent
a. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written (signed and dated) obtained before any study-related activities are performed.
General Health
Smoking/Caffeine/Alcohol
Exclusion Criteria:
Medical History
Medications
i. Subjects are permitted to take hormonal and hormone replacement therapy at acceptable levels if stable at least 30 days prior to Day -1, through the duration of the study, and for 30 days after the study ends.
ii. Acetaminophen (up to 2 grams per day) may be used during the study under the direction of the Investigator.
iii. COVID vaccine is allowed if taken at least 45 days prior to Day -1 iv. On a case-by-case basis, an Investigator is permitted to allow the use of certain concomitant medications, for example, to treat an AE, as long as an Investigator determines that the medication will not affect the subject's safety or study integrity (e.g., topical medications).
Alcohol/Substance Abuse
Allergy/Intolerance
a. Subject has a history of allergy to d-MPH, to any component of the dosage form, or any other allergy, which, in the opinion of an Investigator, contraindicates their participation.
Clinical Studies
a. Receipt of an drug within the 30 days before screening day. b. Previous participation in a CTx-1301 study.
Personnel
a. An employee of the sponsor, study site, or members of their immediate family.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive CTx-1301 in a fasted state.
Drug: Dexmethylphenidate
Subjects will receive CTx-1301 in a fed state (high fat test meal).
Drug: Dexmethylphenidate
Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
Pharmacokinetic parameter (Cmax)
Maximum Concentration
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter (AUC0-inf)
Area Under the Curve from time 0 to infinity
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter (AUC0-last)
Area Under the Curve from time 0 to 28 hrs
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter K
Terminal Elimination Constant
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter T 1/2
Half Life
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter T max
Time of Maximum Concentration
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter T lag
Lag time
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter Cl/F
Apparent Clearance
Time frame: Hour 0 to hour 28
Pharmacokinetic parameter Vd/F
Apparent Volume of Distribution
Time frame: Hour 0 to hour 28
Partial AUC
Area Under the Curve
Time frame: 0-3 hrs
Partial AUC
Area Under the Curve
Time frame: 3-6 hrs
Partial AUC
Area Under the Curve
Time frame: 3-7 hrs
Partial AUC
Area Under the Curve
Time frame: 6-9 hrs
Partial AUC
Area Under the Curve
Time frame: 7-12 hrs
Partial AUC
Area Under the Curve
Time frame: 9-12 hrs
Partial AUC
Area Under the Curve
Time frame: 12-16 hrs
Safety - ECG
Evaluation of changes in ECG measurements
Time frame: Day -1 to Day 4
Safety - Vital Signs
Evaluation of changes in Vital Sign measurements
Time frame: Day -1 to Day 4
Safety - Safety Labs
Evaluation of changes in Safety Lab measurements
Time frame: Day -1 to Day 4
Safety - Physical Exam
Evaluation of changes in the Physical Exam
Time frame: Day -1 to Day 4
Safety - C-SSRS
Evaluation of changes in the Suicidal Ideation
Time frame: Day -1 to Day 4
Safety - Treatment Emergent Adverse Events (TEAEs)
Evaluation of Treatment Emergent Adverse Events (TEAEs)
Time frame: Day -1 to Day 4
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Oct 2022, 1 month.
Of 18 phase 1 interventional studies under Fasting, half reached primary completion within 1 month of starting (the median), counting those still running; a quarter within 0 and three quarters within 3. This study's 1 month is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmethylphenidate
Cingulate Therapeutics